Miosan

Quick links to important sections

Miosan

Method of action: Miorelaxant, Muscle Relaxant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miosan

What is Miosan?

Miosan is a medication primarily utilized for the treatment of muscle spasms associated with acute, painful musculoskeletal conditions. It belongs to a class of drugs known as skeletal muscle relaxants. The active ingredient in Miosan is cyclobenzaprine hydrochloride.

Mechanism of Action

Miosan works by acting on the central nervous system, specifically at the brain stem level. Unlike some other treatments, it does not act directly on the muscles themselves or the motor end plate. By influencing the transmission of nerve impulses, the medication helps to reduce tonic somatic motor activity, which in turn alleviates muscle spasms and the associated pain.

Therapeutic Use

The medication is typically prescribed as an adjunct to rest and physical therapy. It is designed for short-term use to manage symptoms such as:

  • Localized muscle pain
  • Reduced range of motion caused by muscle stiffness
  • Tension associated with acute injuries or strains

It is important to note that Miosan is intended for the relief of discomfort related to acute musculoskeletal issues and is generally not indicated for the treatment of muscle spasms caused by cerebral or spinal cord disease.

Regulatory References

  1. Cyclobenzaprine - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Miosan?

Possible Side Effects and Safety Information

The official safety profile for Miosan (Cyclobenzaprine Hydrochloride) is structured by regulatory bodies to communicate potential adverse reactions and constraints on use. The most frequently documented effects, classified as Common in regulatory information, are associated with the Central Nervous System and anticholinergic activity, reflecting the medicine’s central action.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common (ge 3%) Drowsiness, Dry Mouth, Dizziness, Fatigue, Constipation, Nausea, Confusion
Uncommon (ge 1%) Headache, Blurred Vision, Insomnia, Asthenia
Rare/Post-marketing Serotonin Syndrome, Seizures, Hepatitis, Jaundice

Serious Adverse Reactions and Restrictions

Regulatory documents highlight Serotonin Syndrome, Seizures, and severe hypersensitivity reactions (e.g., Anaphylaxis) as clinically significant, rare adverse reactions. The medicine is contraindicated for use in individuals taking Monoamine Oxidase Inhibitors (MAOIs) concurrently or within 14 days, and in patients with certain pre-existing conditions including Hyperthyroidism, Congestive Heart Failure, or during the recovery phase of acute myocardial infarction.


Population and Time-Related Safety

Official labeling notes that the clearance of the drug is reduced in individuals with Hepatic Impairment, often requiring restricted use or caution. Older Adults may experience increased susceptibility to CNS and anticholinergic effects. The safety profile supports the use of Miosan for short-term periods only, and common effects such as drowsiness may be more noticeable at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes cyclobenzaprine (Miosan) overdose as having the potential for serious and rapidly developing toxicity, mandating immediate attention. The most common manifestations documented in official labeling include drowsiness, tachycardia (fast heart rate), agitation, tremor, and confusion.

Critical Manifestations and Emergency Action

Severe, potentially life-threatening outcomes reported in regulatory documents include cardiac arrest, cardiac dysrhythmias, severe hypotension, and seizures. The possibility of developing Serotonin Syndrome is also listed. Because of this risk, individuals must seek emergency medical attention immediately when an overdose is suspected.

Management is largely symptomatic and supportive, as no specific antidote is known. Hospital monitoring, including immediate and continuous ECG monitoring, is required for all suspected overdose cases due to the risk of cardiotoxicity, including changes in QRS axis or width. Official procedural steps involve initiating gastrointestinal decontamination with measures such as gastric lavage followed by activated charcoal.

Overdose risk is noted to be increased in the elderly and in patients with hepatic impairment, making these populations more susceptible to adverse effects. Multiple drug ingestions, including alcohol, are also associated with increased risk.

Therapeutic Uses of Miosan

Miosan (Cyclobenzaprine) is commonly used for managing the short-term discomfort of acute, painful conditions involving skeletal muscle spasm. It is applied across domains where additional symptomatic support is needed alongside rest and physical therapy to address the immediate symptom burden. The medication is utilized in clinical settings marked by temporary physiological imbalance following an acute musculoskeletal event.

Managing Acute Muscle Spasm and Rigidity

This medication is relevant for symptomatic relief from the involuntary, painful tightening of muscles, and is applied to address symptoms associated with conditions such as acute muscle strains, sprains, and localized discomfort in the low back or neck. By helping to ease the spasm, Miosan supports the patient during manifestations of associated muscular rigidity and localized stiffness.

Supporting Comfort and Functional Stability

The primary application of this supportive therapy is to help ease discomfort and restriction that the acute spasm imposes on the patient, providing supportive relief when symptoms interfere with routine activities. This support supports the patient during episodes of heightened discomfort and may assist with participation in recommended recovery measures.

Quick Fact: Symptomatic Support in Acute Skeletal Muscle Spasm

Regulatory References

  1. DailyMed, a service of the NIH,

Eligibility and Restrictions for Use

Who Can and Cannot Use Miosan? Official Eligibility

The eligibility for using Miosan (Cyclobenzaprine) is strictly defined by regulatory documents, focusing on patient age, underlying health conditions, and current medications. The medication is established for use in adults and pediatric patients 15 years of age and older. Safety and effectiveness have not been established for children under 15.

Contraindicated Populations

Use of Miosan is prohibited (contraindicated) in patients with the following conditions or circumstances:

  • Known hypersensitivity to cyclobenzaprine.
  • Use of Monoamine Oxidase (MAO) inhibitors within 14 days.
  • Specific cardiovascular conditions, including congestive heart failure, arrhythmias, heart block, conduction disturbances, or the acute recovery phase of myocardial infarction.
  • Hyperthyroidism (overactive thyroid).

Use Restrictions and Special Considerations

Population Group Regulatory Status
Older Adults (Geriatric) Use requires caution; the extended-release formulation is not recommended.
Hepatic Impairment Use is not recommended for moderate to severe impairment; requires caution for mild impairment.
Pregnancy Classified as Category B; use is permitted only if clearly needed.
Lactation Caution is advised as it is unknown if the drug is excreted in human milk.

Additionally, Miosan is not effective for spasticity related to cerebral or spinal cord disease. The regulatory profile establishes clear boundaries to limit use to the approved population for the short-term relief of acute muscle spasm.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Miosan (Cyclobenzaprine) based on three key domains: formal prohibition, additive effects, and altered plasma clearance.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, and a mandatory 14-day separation period is required after stopping MAOI therapy before initiating Miosan. This strict timing rule addresses the risk of severe reactions, including hyperpyretic crisis.

Pharmacodynamic interactions primarily involve additive effects. Combining Miosan with Central Nervous System (CNS) depressants—such as alcohol (ethanol), barbiturates, or opioid analgesics—results in enhanced CNS depression. Furthermore, co-administration with other serotonergic drugs (e.g., SSRIs, SNRIs, Tramadol) carries a documented risk of Serotonin Syndrome.

Interaction classifications also address pharmacokinetic clearance modification. Patients with mild hepatic impairment exhibit significantly reduced clearance, resulting in cyclobenzaprine plasma levels that are approximately two-fold higher than in healthy individuals. This reduced clearance leading to increased systemic exposure is a stated constraint for use in this population, as is the observed 40% increase in exposure for the extended-release formulation in the elderly population. The drug's inherent anticholinergic action may also be potentiated by concurrent use of other anticholinergic agents.

Mechanism of Action

Central Modulation of Descending Motor Pathways

The core mechanism involves acting in the Central Nervous System (CNS), specifically within the brainstem, where the active molecule functions as an antagonist primarily at the 5-HT 2A serotonin receptors. This molecular action modulates the activity of the descending monoaminergic pathways that control motor output, contributing to the reduction of tonic somatic motor activity.


Attenuation of Spinal Motor Neuron Excitability

This supraspinal modulation leads to a decrease in excitatory input delivered to the alpha and gamma motor neurons located in the spinal cord's ventral horn. By depressing the polysynaptic reflexes at this level, the molecule effectively lowers the overall reflex excitability of these motor neurons, which results in lower tonic somatic motor activity of the skeletal muscle.


Secondary CNS Receptor Engagement

The molecule also engages other central targets, including acting as an antagonist at the H 1 histamine receptors and muscarinic cholinergic receptors. These secondary binding events contribute to a broader central depressant effect and a generalized lowering of CNS arousal levels, which occurs concurrently with the primary motor control modulation.

Dosage and Administration Information

Miosan, whose active ingredient is cyclobenzaprine, is administered by the oral route and is prescribed for short-term use only, limited to a period of up to two or three weeks. This duration is established because effectiveness for more prolonged periods has not been adequately demonstrated, as acute muscle spasms are typically short-lived.


The medication is available in two main oral forms, each with a distinct dosing regimen:

Form & Strengths Standard Adult Dosing & Frequency
Immediate-Release (IR) Tablet (5 mg, 10 mg) 5 mg orally three times a day (t.i.d.). The dose may be increased to 10 mg t.i.d. The total daily dosage must not exceed 60 mg per day.
Extended-Release (ER) Capsule (15 mg, 30 mg) 15 mg orally once daily. May be increased to a maximum of 30 mg once daily. Doses should be taken at approximately the same time each day.

Administration Details

The ER capsule must be swallowed intact (whole). Alternatively, the contents may be sprinkled onto one tablespoon of applesauce and the mixture consumed immediately without chewing the granules. The IR tablets can be taken with or without food. If a dose is missed, it should be taken as soon as remembered, but double doses should not be taken to compensate.

Population-Specific Rules

Specific adjustments are required for certain populations. For older adults (65 years and over) or patients with mild hepatic impairment, therapy using the IR tablet should begin at the 5 mg dose with slow upward adjustment. Use of the ER capsule is not recommended for geriatric patients or in cases of moderate to severe hepatic impairment, as these conditions may prolong the drug's plasma half-life.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Miosan

Evidence for Acute Muscle Spasm (Low Back and Neck)

Miosan was studied alongside rest and physical therapy in the context of acute muscle spasm. This evidence has mostly been conducted through short-term Randomized Controlled Trials (RCTs), where researchers monitored outcomes over periods of typically one to two weeks. These studies included adult patients experiencing outcomes related to physical discomfort and muscle spasms, such as in the low back and neck. Researchers monitored patient-reported outcomes describing perceived discomfort, as well as assessments of functional activity level and global change.

Studies conducted during periods of increased symptom activity reported patterns suggesting an association with short-term changes in these observed outcomes. Reported differences in measured outcomes were often observed early in the treatment course. The overall evidence quality is subject to several factors, including study design limitations, and many of the earlier trials were noted to have methodological limitations, such as relatively small sample sizes.


Evidence for Chronic Pain Conditions (Fibromyalgia and Myofascial Pain)

Miosan was studied for chronic conditions characterized by fluctuating or episodic manifestations. These studies comprised a small number of small-scale RCTs. The findings were mixed and data are still emerging in this area. Findings describe patterns observed in these studies over follow-up durations that sometimes extended for several weeks. The available evidence provides limited insight into the long-term management of these chronic conditions using the immediate-release tablet.


What Is Still Uncertain About Miosan Research

The vast majority of controlled studies involved limited follow-up durations, typically observing patients only up to 14 days. Consequently, long-term effects are not fully established. Furthermore, comparative evidence is lacking in some areas, meaning few studies have directly compared Miosan against contemporary combinations of rest and physical therapy. Data for certain groups, such as older adults, remain limited, and research on outcomes related to daily functioning or activity level over extended timeframes is lacking. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Cyclobenzaprine Hydrochloride Tablet, film coated - Prescribing Information (US FDA Approved Labeling)

Frequently Asked Questions (FAQ)

Common questions about Miosan (FAQ)


Q: How quickly can I expect Miosan to start working?

Official prescribing information indicates that the immediate-release tablet typically begins to relieve muscle spasm pain within 30 to 60 minutes after being taken. However, the full therapeutic effect of Miosan may take up to seven days to be realized.


Q: What happens if I forget to take a dose of Miosan?

According to the official product information, if a dose is missed, it should be taken as soon as you remember, unless it is almost time for your next scheduled dose. Regulatory documents indicate that double doses should not be taken to compensate for a missed dose.


Q: Does Miosan interact with common over-the-counter pain relievers?

Regulatory information generally shows no major prohibition with common non-opioid pain relievers like ibuprofen or acetaminophen. However, combining Miosan with other medicines may potentially increase the risk of central nervous system (CNS) side effects, such as feeling dizzy or drowsy.


Q: What is the difference between Miosan and similar medications mentioned online?

Miosan is officially classified as a centrally acting skeletal muscle relaxant. This means it works primarily by influencing nerve activity in the brain and spinal cord, rather than directly on the muscle itself. It is also structurally similar to tricyclic antidepressants.


Q: What should I do if the side effects of Miosan feel too strong?

Official patient information states that if symptoms like swelling, difficulty breathing, rash, or signs of Serotonin Syndrome (such as confusion, fever, or fast heart rate) are experienced, these serious reactions require immediate professional medical attention. Severe reactions are considered rare but need urgent care.


Q: Is the drowsiness from Miosan expected to decrease over time?

Drowsiness is noted as a very common side effect. Official labeling states that effects like drowsiness and sedation may be more noticeable at the start of treatment. The observation that effects are stronger initially suggests this effect may decrease over time, although individual experiences vary.


Q: Can Miosan cause changes in my sleep patterns?

Official documents list insomnia (difficulty sleeping) as an uncommon side effect of the medication. The drug's central depressant effects may also influence sleep patterns, which can sometimes be helpful when muscle spasms are causing nocturnal disruption.


Q: Is Miosan the same type of medicine as muscle relaxants I've taken before?

Miosan is categorized as a centrally acting skeletal muscle relaxant. This classification indicates that its primary action is in the central nervous system (brainstem and spinal cord) to regulate motor activity, which is a different mechanism than drugs that act directly at the neuromuscular level.


Q: Is Miosan considered a controlled substance?

According to the U.S. Drug Enforcement Administration (DEA) and federal regulatory statuses, Miosan (cyclobenzaprine) is not classified as a controlled substance.


Q: Do I need to stop taking Miosan slowly, or can I stop all at once?

Stopping the medication abruptly after prolonged use may lead to mild symptoms such as headache, nausea, and general discomfort. Because Miosan is only recommended for short-term use (up to three weeks), this potential issue is generally minimized.


Q: Is Miosan safe to use if I have an underlying heart condition?

Official regulatory documents state that Miosan is prohibited (contraindicated) for patients with specific heart conditions. These include congestive heart failure, certain heart rhythm problems (arrhythmias), conduction disturbances, or those in the acute recovery phase following a heart attack.


Q: How is Miosan eliminated from the body?

The active ingredient in Miosan is extensively broken down, or metabolized, in the liver. It is then eliminated from the body primarily through the urine in the form of inactive compounds.


Q: Does Miosan work better if taken with food?

Official guidance states that the immediate-release tablet can be taken with or without food. There is no official information stating that taking it with food results in a better therapeutic effect, although taking it with food may help to avoid an upset stomach.


Q: Is Miosan meant for short-term use only?

Yes, regulatory documents clearly state that Miosan is recommended only for short-term use, which is typically limited to a period of two or three weeks. There is currently no adequate evidence of effectiveness available to support its use for longer periods.


Q: Why is Miosan sometimes mentioned in connection with fibromyalgia?

Studies have examined Miosan’s potential use for chronic conditions such as fibromyalgia. However, official regulatory documents note that the findings from these studies were mixed, and the drug is not approved for the management of these chronic conditions.


Q: Can Miosan be taken while breastfeeding?

Caution is advised for use during lactation. While the amount of the active ingredient that transfers into human milk appears to be very small, monitoring the infant for any potential effects is noted as a necessary precaution.


Q: Does Miosan affect blood pressure?

Due to its structural relationship to tricyclic antidepressants, the medication is associated with effects on the cardiovascular system. These effects can include changes in heart rate, as well as documented occurrences of both high blood pressure (hypertension) and low blood pressure (hypotension).


Q: Is it okay to take Miosan if I also take anti-depressants?

Official drug interaction information notes that combining Miosan with certain serotonergic drugs, such as some types of antidepressants (SSRIs or SNRIs), carries a documented risk. This combination may lead to a serious condition known as Serotonin Syndrome.


Q: Does taking Miosan make certain medical conditions worse?

The medication is prohibited (contraindicated) for patients with conditions such as hyperthyroidism (an overactive thyroid) or certain heart problems, as its use could potentially worsen these pre-existing conditions or pose a serious safety risk.


Q: How does Miosan work on the central nervous system?

Miosan is a centrally acting drug that works primarily in the central nervous system, specifically the brainstem. Its function is to reduce the excessive nerve activity that contributes to muscle spasms, helping to lower overall muscle tone and tension.


Q: Do studies suggest Miosan works for chronic or acute issues?

Miosan is indicated only as an adjunct therapy for muscle spasm associated with acute (short-term) musculoskeletal conditions. Official evidence does not support its use for the long-term management of chronic issues.

How should Miosan be stored and disposed of?

The storage and disposal of Miosan (Cyclobenzaprine Hydrochloride) must adhere to conditions specified in official regulatory labeling to ensure product integrity and safety.

Storage Conditions

Storage Requirement Details
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect the tablets from moisture and excessive heat.
Container Keep the medicine in a tightly closed container.
Child Safety Store Miosan out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Miosan, a drug take-back program is the preferred method, as stated in governmental instructions. If a take-back program is unavailable, the medicine can be discarded in the household trash only after being mixed with an undesirable substance, such as dirt or used coffee grounds, and sealed in a bag. The medicine must not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miosan found in:

A-Z Index: